Patents by Inventor Jill Marie Sturdivant

Jill Marie Sturdivant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amino acid salts of prostaglandins
    Patent number: 8722739
    Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: May 13, 2014
    Assignee: Novaer Holdings, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant
  • Dual mechanism inhibitors for the treatment of disease
    Patent number: 8716310
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: May 6, 2014
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • AMINO ACID SALTS OF PROSTAGLANDINS
    Publication number: 20140031423
    Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 30, 2014
    Applicant: NOVAER HOLDINGS, INC.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant
  • Amino acid salts of prostaglandins
    Patent number: 8623918
    Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: January 7, 2014
    Assignee: Novaer Holdings, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant
  • Amino acid salts of prostaglandins
    Patent number: 8470882
    Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: June 25, 2013
    Assignee: Novaer Holdings, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant
  • 6-and 7-amino isoquinoline compounds and methods for making and using the same
    Patent number: 8455514
    Abstract: 6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: June 4, 2013
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Geoffrey Richard Heintzelman, Susan M. Royalty
  • 6-aminoisoquinoline compounds
    Patent number: 8455647
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: June 4, 2013
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Geoffrey Richard Heintzelman, Susan M. Royalty
  • 6-aminoisoquinoline compounds
    Patent number: 8455513
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: June 4, 2013
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
  • Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
    Patent number: 8450344
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: May 28, 2013
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Dual mechanism inhibitors for the treatment of disease
    Patent number: 8394826
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: March 12, 2013
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • 6-aminoisoquinoline compounds
    Patent number: 8357699
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: January 22, 2013
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
  • BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS
    Publication number: 20120196916
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Application
    Filed: April 9, 2012
    Publication date: August 2, 2012
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • DUAL-ACTION INHBITORS AND METHODS OF USING SAME
    Publication number: 20120135984
    Abstract: Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.
    Type: Application
    Filed: May 1, 2010
    Publication date: May 31, 2012
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty, Geoffrey Richard Heintzelman, Jeffrey D. Yingling, Casey Kopczynski
  • Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
    Patent number: 8153656
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: April 10, 2012
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • 6-and 7-amino isoquinoline compounds and methods for making and using the same
    Patent number: 8153654
    Abstract: 6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: April 10, 2012
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Geoffrey Richard Heintzelman, Susan M. Royalty
  • 6-Aminoisoquinoline Compounds
    Publication number: 20110319390
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Application
    Filed: September 12, 2011
    Publication date: December 29, 2011
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Geoffrey Richard Heintzelman, Susan M. Royalty
  • 6-aminoisoquinoline compounds
    Patent number: 8034943
    Abstract: 6-Aminoisoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: October 11, 2011
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Geoffrey Richard Heintzelman, Susan M. Royalty
  • 6-AMINOISOQUINOLINE COMPOUNDS
    Publication number: 20110183965
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Application
    Filed: January 31, 2011
    Publication date: July 28, 2011
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
  • DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20100280011
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: January 27, 2010
    Publication date: November 4, 2010
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME
    Publication number: 20100168176
    Abstract: Compounds having the following general formula, pharmaceutical compositions comprising the compounds, and methods of treating cancer, obesity, and microbial infections using such compositions: wherein: R1=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, cyanomethyl, —OCH3, OC(O)CH3 or OC(O)CF3 R2=-OCH2C(O)NHNH—R5, where R5 is (a) phenyl, optionally substituted with one or more of halogen, C1-C8 alkyl, optionally substituted with halogen, —OH, —OR6, where R6 is C1-C8 alkyl, optionally substituted with halogen, or (b) 2-, 3-, or 4-pyridyl, optionally substituted with halogen, —OH, —OR6, where R6 is C1-C8 alkyl, optionally substituted with halogen, or (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidazole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; or (d) —C(O)R7, where R7 is a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or a heterocycle selected from the group consisting of pyridyl, imidazole, thiazole, benzimi
    Type: Application
    Filed: November 8, 2007
    Publication date: July 1, 2010
    Applicants: FASGEN LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Craig Townsend, Francis Kuhajda, Kandasamy Subburaj, Jill Marie Sturdivant